Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 14,055 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 14,055 shares of the stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $27.44, for a total value of $385,669.20. Following the completion of the sale, the insider owned 44,089 shares of the company’s stock, valued at approximately $1,209,802.16. This trade represents a 24.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

David Malcom Rodman also recently made the following trade(s):

• On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.99, for a total value of $184,057.51.
• On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $30.21, for a total value of $65,585.91.
• On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.10, for a total transaction of $13,353.60.
• On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.61, for a total transaction of $370,677.87.
• On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.75, for a total transaction of $252,469.75.
• On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.32, for a total transaction of $205,167.36.
• On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $33.27, for a total transaction of $72,195.90.
• On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.87, for a total transaction of $2,512,227.19.
• On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.02, for a total transaction of $6,748,879.30.

Mineralys Therapeutics Price Performance

NASDAQ:MLYS opened at $27.60 on Friday. The firm has a 50-day moving average of $33.89 and a two-hundred day moving average of $33.41. The stock has a market cap of $2.18 billion, a P/E ratio of -9.36 and a beta of 0.51. Mineralys Therapeutics, Inc. has a 1-year low of $8.24 and a 1-year high of $47.65.

Institutional Investors Weigh In On Mineralys Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Navalign LLC acquired a new stake in shares of Mineralys Therapeutics in the fourth quarter valued at approximately $33,000. Smartleaf Asset Management LLC raised its holdings in Mineralys Therapeutics by 198.2% during the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock worth $40,000 after purchasing an additional 676 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in Mineralys Therapeutics by 42.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock worth $54,000 after purchasing an additional 1,197 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in Mineralys Therapeutics by 1,845.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock valued at $76,000 after purchasing an additional 1,993 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Mineralys Therapeutics during the 2nd quarter valued at $91,000. 84.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MLYS has been the topic of several analyst reports. Wells Fargo & Company lifted their price objective on Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Thursday, January 22nd. HC Wainwright upped their price target on shares of Mineralys Therapeutics from $52.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Finally, Stifel Nicolaus increased their price objective on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $47.43.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.